But more broadly, the technology could revolutionize many areas of ... The COVID-19 vaccines manufactured by Pfizer-BioNTech ...

Key market opportunities in the shingles vaccine sector include rising elderly populations; expanding healthcare ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Getting covid-19 for the first time slightly increased the risk of heart inflammation, blood clots and bleeding disorders among children, whereas being vaccinated against the virus was much safer and ...

Pfizer Inc. (NYSE:PFE) strengthens its global pharmaceutical leadership and research presence in the S&P 500 Index.

At a margin of 40%, Palantir delivered $476 million net income (GAAP). Overall, the company now has $6.4 billion in cash and cash equivalents. More importantly for investors, Palantir raised its FY ...

The first full week of November delivers a broad and high-impact earnings lineup across semiconductors, cloud software, AI, ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The journal Nature has reported that mRNA vaccines used to treat Covid-19 may prolong the lives of people with cancer who ...

Acuitas Therapeutics recently announced the publication of a new study inMolecular Therapy - Nucleic Acids, titled "mRNA-LNP ...

Michael Burry’s sizable put options on PLTR suggest cautious skepticism, even as the stock’s memetic narrative fuels ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.